Michael May
Vorstandsvorsitzender bei Centre For Commercialization of Regenerative Medicine
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Guy Sauvageau | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
David Millette | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Parimal Nathwani | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | 15 Jahre |
Peter Zandstra | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Cynthia Lavoie | M | - |
CCRM Enterprises Inc
| 4 Jahre |
Michael Nobrega | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.
University of Toronto
| 5 Jahre |
Angus J. Grant | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Michael S. Robinson | M | - |
20/20 Vision Centers, Inc.
20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services 20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT. | - |
Robert Howard | M | 100 |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Denis Godin | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Mario Piccinin | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Philip Vanek | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | 9 Jahre |
Donna Wall | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Mitchel Sivilotti | M | - |
Omniabio, Inc.
Omniabio, Inc. BiotechnologyHealth Technology Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti. | - |
Karin Flyborg | F | 63 |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Sofia Hjelmberg | F | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | 1 Jahre |
Sohaib Siddiqui | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | 4 Jahre |
Anne Marinier | F | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
David S. Smith | M | - |
Foundation For Cell & Gene Medicine
| - |
Leah Cowen | F | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Christopher Paige | M | 71 |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Douglas Heintzman | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Echo Pan | F | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Ronald Close | M | 65 |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Richard D. Cherney | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Reni J. Benjamin | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Michael Hanley | M | 58 |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Vivek Goel | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Joan Sheehan | F | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Nadine Beauger | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Claudia Zylberberg | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | - |
Mark Zdziebko | M | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Jessica Chutter | F | - |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Zheng-Hong Lu | M | - |
University of Toronto
| 26 Jahre |
Kim Warren | M | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | 9 Jahre |
Samantha Nutt | M | - |
University of Toronto
| 27 Jahre |
Peter Pisters | M | 63 |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | - |
Sven Kili | M | 57 |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | 7 Jahre |
Eugene Lucas Fiume | M | 66 |
University of Toronto
| 29 Jahre |
Jana Machan | F | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | 7 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Joanne Hackett | M | 45 | - | |
George Babu | M | - |
University of Toronto
| 15 Jahre |
Andrea Park | F | 52 | - | |
Jae K. Kim | M | - |
University of Toronto
| 5 Jahre |
Daniel M. Miller | M | - |
University of Toronto
| 2 Jahre |
Eric Josipovic | M | - |
University of Toronto
| 6 Jahre |
Joshua Gerstein | M | 51 |
University of Toronto
| 3 Jahre |
Annalisa Jenkins | M | 58 | 3 Jahre | |
Michael Dolega | M | - |
University of Toronto
| 7 Jahre |
Natasha Ann Sharpe | M | - |
University of Toronto
| - |
Tom Keefe | M | - |
University of Toronto
| 5 Jahre |
Meny Grauman | M | - |
University of Toronto
| 6 Jahre |
Greg Payne | M | - |
University of Toronto
| 14 Jahre |
Ricky Mehra | M | 45 |
University of Toronto
| 7 Jahre |
Sandy Der | M | - |
University of Toronto
| 13 Jahre |
Peng Fu | M | - |
University of Toronto
| 5 Jahre |
Robin Bienenstock | M | 55 |
University of Toronto
| 1 Jahre |
Russell Skibsted | M | 65 | - | |
Alfred C. Sum | M | - |
University of Toronto
| 6 Jahre |
Jean-Christophe Renondin | M | - | - | |
Neil Seneviratne | M | - |
University of Toronto
| 4 Jahre |
John Docherty | M | 53 |
University of Toronto
| 6 Jahre |
Hussein Sunderji | M | - |
University of Toronto
| 9 Jahre |
Matthew Come | M | 67 |
University of Toronto
| 3 Jahre |
Anne Hua | F | - |
University of Toronto
| 7 Jahre |
Meredith Brill | F | 49 |
University of Toronto
| 4 Jahre |
Jade Rubick | M | - |
University of Toronto
| 3 Jahre |
Douglas Ching | M | - |
University of Toronto
| 4 Jahre |
David Klein | M | - |
University of Toronto
| 4 Jahre |
Pui Yin Fong | F | 53 |
University of Toronto
| 4 Jahre |
George Lagoudakis | M | - |
University of Toronto
| 4 Jahre |
Yvonne Johnson | F | - |
University of Toronto
| 5 Jahre |
Peter Bures | M | 47 |
University of Toronto
| 4 Jahre |
John Maletic | M | - |
University of Toronto
| 4 Jahre |
Mina Debra Marmor | M | - |
University of Toronto
| 3 Jahre |
Feng Guo | M | 54 |
University of Toronto
| 3 Jahre |
Ronan Levy | M | 45 |
University of Toronto
| 4 Jahre |
Sonia Gokhale | F | - |
University of Toronto
| 4 Jahre |
Mike Vanderburgh | M | - |
University of Toronto
| 2 Jahre |
Asya Bradley | F | - |
University of Toronto
| 4 Jahre |
Carey MacRury | M | - |
University of Toronto
| 4 Jahre |
Brian Cooke | M | - |
University of Toronto
| 4 Jahre |
Wing Tung Chow | M | 49 |
University of Toronto
| 4 Jahre |
Curtis Wee | M | - |
University of Toronto
| 4 Jahre |
Rabinder Grewal | F | - |
University of Toronto
| 4 Jahre |
Jillian Kovensky | M | - |
University of Toronto
| 4 Jahre |
Keyvan Mohajer | M | 46 |
University of Toronto
| 4 Jahre |
Bryce Bradley | F | 53 |
University of Toronto
| 4 Jahre |
Charles Walter Lannon | M | - |
University of Toronto
| 4 Jahre |
Zhao Jie Li | M | 69 |
University of Toronto
| 3 Jahre |
Wai Leung Chan | M | 51 |
University of Toronto
| 4 Jahre |
Rick Lau | M | - |
University of Toronto
| 4 Jahre |
Carmen Tang | F | - |
University of Toronto
| 3 Jahre |
Johnson Wan | M | 44 |
University of Toronto
| 4 Jahre |
Dorothy Dudek | F | - |
University of Toronto
| 4 Jahre |
Beata Antoszek | F | - |
University of Toronto
| 4 Jahre |
Dan Brennand | M | - |
University of Toronto
| 1 Jahre |
Feisal Afzal | M | - |
University of Toronto
| 4 Jahre |
Mark T. Smethurst | M | 55 |
University of Toronto
| 4 Jahre |
Tyler Currie | M | - |
University of Toronto
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Kanada | 93 | 93,00% |
Vereinigte Staaten | 7 | 7,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael May
- Persönliches Netzwerk